MAIA Biotechnology Inc(MAIA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 5:40 PM ET (Korea 10/30 06:40)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.63 | Insider Own | 16.98% | Shs Outstand | 60.8M | Perf Week | 4.42% |
| Market Cap | 0.07B | Forward P/E | 1.06 | EPS next Y | 305.56% | Insider Trans | 4.05% | Shs Float | 51.3M | Perf Month | - |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.13 | Inst Own | 22.02% | Short Float | 4.92% | Perf Quarter | -5.6% |
| Income | -0.03B | P/S | - | EPS this Y | 22.86% | Inst Trans | 7.16% | Short Ratio | 5.45 | Perf Half Y | -11.28% |
| Sales | 0.00B | P/B | 3.47 | EPS next 5Y | - | ROA | -136.67% | Short Interest | 2.52M | Perf YTD | -22.88% |
| Book/sh | 0.34 | P/C | 2.64 | EPS past 3/5Y | 26.39% -2.25% | ROE | -218.68% | 52W High | -63.01% ($3.19) | Perf Year | -9.23% |
| Cash/sh | 0.45 | P/FCF | - | Sales past 3/5Y | - | ROIC | -129.84% | 52W Low | 35.63% ($0.87) | Perf 3Y | -37.57% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -7.28% | Gross Margin | - | Volatility(W/M) | 4.79% 4.77% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.06 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.51 | EPS Q/Q | 25.95% | Profit Margin | - | RSI (14) | 50.07 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.51 | Sales Q/Q | - | SMA20 | 2.52% ($1.15) | Beta | 0.28 | Target Price | $14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/11 | SMA50 | -5.63% ($1.25) | Rel Volume | 0.37 | Prev Close | $1.16 |
| Employees | 13 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -18.18% - | SMA200 | -19.3% ($1.46) | Avg Volume(3M) | 0.46M | Price | $1.18 |
| IPO | 2022/7/28 | Option/Short | No/Yes | Trades | 358 | Volume | 170,189 | Change | 1.72% |
🧬 This US clinical-stage biotech company develops novel mechanism-of-action anticancer drug candidates aimed at extending the survival of cancer patients. It focuses on targeted therapy and immuno-oncology, and advances its pipeline through a structure in which each drug candidate is housed in a dedicated R&D subsidiary that shares the parent company's personnel and infrastructure.
Over the past 1 year, on the lower side
63% below its 1-year high.
Traded less than usual. That is 37% of its average volume.
MAIA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +22.9% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -37.6%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #385 of 594 in the industry
Based on market cap of $73M.
ACRV#384 Acrivon Therapeutics Inc $75M PER - MAIA#385 MAIA Biotechnology Inc $73M PER - 
NMRA#386 Neumora Therapeutics Inc $72M PER - 
TELO#387 Telomir Pharmaceuticals Inc $71M PER - 
CRDF#388 Cardiff Oncology Inc $71M PER - 
FAQ
What kind of company is MAIA?
MAIA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MAIA?
The market cap of MAIA is approximately $73M, ranking 4,674 within its sector.
What is the 52-week high and low for MAIA?
MAIA has recorded a 52-week high of $3.19 and a low of $0.87.
